{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:18:38Z","timestamp":1779297518424,"version":"3.51.4"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Description of immune landscapes in malignant microenvironment is critical to the improvement of therapeutic strategies for various tumors. Acute myeloid leukemia (AML) remains a severe life-threatening malignancy and often confronts treatment dilemma in clinic. Although \u03b3\u03b4 T cells exhibit independent and potent cytotoxicity against leukemic cells <jats:italic>in vitro<\/jats:italic> and in the mouse models, efficacy of \u03b3\u03b4 T cell-based immunotherapy on AML patients has seemed unsatisfying so far. How the anti-AML capacity of \u03b3\u03b4 T cells is suppressed <jats:italic>in vivo<\/jats:italic> remains elusive. Herein, we found an aberrant \u03b3\u03b4 T cells subset expressing CD25<jats:sup>+<\/jats:sup>CD127<jats:sup>low<\/jats:sup>V\u03b42<jats:sup>+<\/jats:sup> in the bone marrows of patients with newly diagnosed AML. The emergence of this subset was significantly associated with disease status and risk stratification as well as with the abnormally increased bone morphogenetic protein 2 (BMP2). Mechanistically, BMP2 could directly induce CD25<jats:sup>+<\/jats:sup>CD127<jats:sup>low<\/jats:sup>V\u03b42<jats:sup>+<\/jats:sup> \u03b3\u03b4 T cells (named as Reg-V\u03b42) <jats:italic>in vitro<\/jats:italic>. The immunosuppressive features of Reg-V\u03b42 cells were identified by combining immunophenotypical and functional data. Furthermore, inhibition of BMP2 pathway significantly blocked the emergence of Reg-V\u03b42 cells and enhanced the anti-AML immunity in humanized mice. These findings not only provide a novel insight into the mechanisms of immunosuppression in the context of leukemia, but also suggest potential targets for the treatment of AML and other hematopoietic malignancies.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1009709","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T05:16:05Z","timestamp":1665983765000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Identification of the immunosuppressive effect of \u03b3\u03b4 T cells correlated to bone morphogenetic protein 2 in acute myeloid leukemia"],"prefix":"10.3389","volume":"13","author":[{"given":"Shuang","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianhui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keli","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2026","article-title":"Advances in acute myeloid leukemia","volume":"375","author":"Newell","year":"2021","journal-title":"BMJ"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.50","article-title":"'Acute myeloid leukemia: A comprehensive review and 2016 update'","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000572","article-title":"Treatment for Relapsed\/Refractory acute myeloid leukemia","volume":"5","author":"Thol","year":"2021","journal-title":"Hemasphere"},{"key":"B4","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41568-019-0153-5","article-title":"Gammadelta T cells: Pleiotropic immune effectors with therapeutic potential in cancer","volume":"19","author":"Silva-Santos","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0139","article-title":"Prospects for immunotherapy of acute myeloid leukemia using \u0393\u03b4 T cells","volume":"9","author":"Halim","year":"2017","journal-title":"Immunotherapy"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00929","article-title":"Molecular determinants of target cell recognition by human gammadelta T cells","volume":"9","author":"Simoes","year":"2018","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1103710","article-title":"Human Vgamma9vdelta2 T cells specifically recognize and kill acute myeloid leukemic blasts","volume":"188","author":"Gertner-Dardenne","year":"2012","journal-title":"J Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nri3904","article-title":"Gammadelta T cells in cancer","volume":"15","author":"Silva-Santos","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41408-021-00572-7","article-title":"Activated naive gammadelta T cells accelerate deep molecular response to bcr-abl inhibitors in patients with chronic myeloid leukemia","volume":"11","author":"Chang","year":"2021","journal-title":"Blood Cancer J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00800","article-title":"Improving the efficiency of Vgamma9vdelta2 T-cell immunotherapy in cancer","volume":"9","author":"Hoeres","year":"2018","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1378-2","article-title":"Gamma-delta (Gammadelta) T cells: Friend or foe in cancer development","volume":"16","author":"Zhao","year":"2018","journal-title":"J Transl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2017.06.003","article-title":"\u0393\u03b4 T cells: Unexpected regulators of cancer development and progression","volume":"3","author":"Fleming","year":"2017","journal-title":"Trends Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nature14282","article-title":"Il-17-Producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis","volume":"522","author":"Coffelt","year":"2015","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.immuni.2014.03.013","article-title":"Gammadeltat17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer","volume":"40","author":"Wu","year":"2014","journal-title":"Immunity"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.cell.2016.07.046","article-title":"Gammadelta T cells support pancreatic oncogenesis by restraining alphabeta T cell activation","volume":"166","author":"Daley","year":"2016","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3003","article-title":"Characterization of immune dysfunction and identification of prognostic immune-related risk factors in acute myeloid leukemia","volume":"26","author":"Tang","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2020.1806868","article-title":"Higher Tigit(+)Cd226(-) gammadelta T cells in patients with acute myeloid leukemia","volume":"51","author":"Jin","year":"2022","journal-title":"Immunol Invest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4612952","article-title":"Characteristic of tigit and dnam-1 expression on Foxp3+ gammadelta T cells in aml patients","volume":"2020","author":"Jin","year":"2020","journal-title":"BioMed Res Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/08977190412331279890","article-title":"Bone morphogenetic proteins","volume":"22","author":"Chen","year":"2004","journal-title":"Growth Factors"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2010.10.003","article-title":"Bone morphogenetic proteins: A critical review","volume":"23","author":"Bragdon","year":"2011","journal-title":"Cell Signal"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.03.002","article-title":"Bone morphogenetic proteins regulate differentiation of human promyelocytic leukemia cells","volume":"37","author":"Topi\u0107","year":"2013","journal-title":"Leukemia Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1042\/BST20140037","article-title":"The role of the bone morphogenetic proteins in leukaemic stem cell persistence","volume":"42","author":"Toofan","year":"2014","journal-title":"Biochem Soc Trans"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-801019","article-title":"Immature cml cells implement a bmp autocrine loop to escape tki treatment","volume":"130","author":"Grockowiak","year":"2017","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2564","article-title":"A role for bmp-induced homeobox gene Mixl1 in acute myelogenous leukemia and identification of type I bmp receptor as a potential target for therapy","volume":"5","author":"Raymond","year":"2014","journal-title":"Oncotarget"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41419-018-1042-7","article-title":"A new signaling cascade linking Bmp4, Bmpr1a, Deltanp73 and nanog impacts on stem-like human cell properties and patient outcome","volume":"9","author":"Voeltzel","year":"2018","journal-title":"Cell Death Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108219","article-title":"Bone morphogenic proteins are immunoregulatory cytokines controlling Foxp3(+) treg cells","volume":"33","author":"Browning","year":"2020","journal-title":"Cell Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901334","article-title":"Cutting edge: Tgf-Beta1 and il-15 induce Foxp3+ gammadelta regulatory T cells in the presence of antigen stimulation","volume":"183","author":"Casetti","year":"2009","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2013.11.009","article-title":"Rapamycin together with tgf-Beta1, il-2 and il-15 induces the generation of functional regulatory gammadeltat cells from human peripheral blood mononuclear cells","volume":"402","author":"Gu","year":"2014","journal-title":"J Immunol Methods"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of aml in adults: 2017 eln recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e000208","DOI":"10.1136\/jitc-2019-000208","article-title":"Immunosuppressant indulges ebv reactivation and related lymphoproliferative disease by inhibiting Vdelta2(+) T cells activities after hematopoietic transplantation for blood malignancies","volume":"8","author":"Liu","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T Cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the tumor microenvironment: Removing obstruction to anticancer immune responses and immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1379642","article-title":"Il-21 promotes the development of a Cd73-positive Vgamma9vdelta2 T cell regulatory population","volume":"7","author":"Barjon","year":"2017","journal-title":"Oncoimmunology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1277305","article-title":"Tumor-infiltrating Cd39(+)Gammadeltatregs are novel immunosuppressive T cells in human colorectal cancer","volume":"6","author":"Hu","year":"2017","journal-title":"Oncoimmunology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates Cd4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/art.39408","article-title":"Phenotypic, functional, and gene expression profiling of peripheral Cd45ra+ and Cd45ro+ Cd4+Cd25+Cd127(Low) treg cells in patients with chronic rheumatoid arthritis","volume":"68","author":"Walter","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1607136113","article-title":"Human Vdelta2 T cells are a major source of interleukin-9","volume":"113","author":"Peters","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1522471","article-title":"Tgf-beta enhances the cytotoxic activity of Vdelta2 T cells","volume":"8","author":"Peters","year":"2019","journal-title":"Oncoimmunology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.6.2005","article-title":"Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of Stat3","volume":"96","author":"Kawamura","year":"2000","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501460","article-title":"Primitive cml cell expansion relies on abnormal levels of bmps provided by the niche and on bmprib overexpression","volume":"122","author":"Laperrousaz","year":"2013","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3665","article-title":"Gammadelta T cells for immune therapy of patients with lymphoid malignancies","volume":"102","author":"Wilhelm","year":"2003","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0199-6","article-title":"Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: A pilot study","volume":"56","author":"Kobayashi","year":"2007","journal-title":"Cancer Immunol Immunother CII"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0199","article-title":"Targeting human {Gamma}Delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer","volume":"67","author":"Dieli","year":"2007","journal-title":"Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318245bb1e","article-title":"Tumor-promoting versus tumor-antagonizing roles of gammadelta T cells in cancer immunotherapy: Results from a prospective phase I\/Ii trial","volume":"35","author":"Kunzmann","year":"2012","journal-title":"J Immunother"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2009.10.021","article-title":"Applications of small molecule bmp inhibitors in physiology and disease","volume":"20","author":"Hong","year":"2009","journal-title":"Cytokine Growth Factor Rev"},{"key":"B50","doi-asserted-by":"publisher","first-page":"a022327","DOI":"10.1101\/cshperspect.a022327","article-title":"Bone morphogenetic protein-based therapeutic approaches","volume":"10","author":"Lowery","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1009709\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T05:16:08Z","timestamp":1665983768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1009709\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2022.1009709"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1009709","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,17]]},"article-number":"1009709"}}